The Novavax Covid-19 vaccine, which goes by the Scrabble-friendly trade name “Nuvaxovid,” has been authorized as a two-dose primary series given three weeks. or roughly only two Scaramuccis apart.

LONDON -- American biotechnology company Novavax announced Monday that its experimental COVID-19 vaccine was more than 90% effective against symptomatic disease in late-stage clinical trials ...

Earlier this month, the U.S. Department of Health and Human Services (HHS) announced that the Biden administration had secured 3.2 million doses of Novavax’s COVID-19 vaccine, which will be made ...

Novavax Inc. said Thursday Jan. 28, 2021 that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well ...

The U.S. Food and Drug Administration on Friday authorized an updated version of the protein-based Novavax COVID-19 vaccine for use in people 12 and up. Doses could be available by the end of next ...

Vaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico.

Novavax is moving closer to being approved in the U.S. as the newest inoculation against COVID-19, raising hopes that its more established technology will win over vaccine skeptics and increase ...

How Novavax is different from other coronavirus vaccines. July 13, ... Novavax is new in the covid-fighting arsenal, but it uses the same technology as more established vaccines.

Novavax Inc. said Thursday Jan. 28, 2021 that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well ...

The FDA authorized an updated version of the protein-based Novavax COVID-19 vaccine for use in people 12 and up. Doses could be available by next week.

The FDA authorized an updated version of the protein-based Novavax COVID-19 vaccine for use in people 12 and up. Doses could be available by next week.